Povofortay®Receives European Approval as the First Once-Daily Oral Therapy for Moderate-to-Severe Hidradenitis Suppurativa in Adults

Incyte Receives European Commission Approval for Povofortay as a Once-Daily Oral Treatment for Moderate to Severe Hidradenitis Suppurativa Incyte has announced that the European Commission (EC) has approved Povofortay® (povorcitinib)…

Read MorePovofortay®Receives European Approval as the First Once-Daily Oral Therapy for Moderate-to-Severe Hidradenitis Suppurativa in Adults

Gilead Broadens Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing Agreement

Gilead Sciences Signs Royalty-Free Licensing Agreements to Support Potential Future Access to Investigational Obeldesivir for Ebola Prevention Gilead Sciences, has announced royalty-free voluntary licensing agreements with three generic pharmaceutical manufacturers…

Read MoreGilead Broadens Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing Agreement

Quanterix Broadens Access to Blood-Based Alzheimer’s Testing Through Exclusive Partnership with Sherman Abrams Laboratory in New Jersey and Surrounding Areas

Quanterix Partners with Sherman Abrams Laboratory to Expand Access to LucentAD Complete Alzheimer’s Blood Testing Across New Jersey and Metro New York Quanterix Corporation, a company developing advanced ultrasensitive biomarker…

Read MoreQuanterix Broadens Access to Blood-Based Alzheimer’s Testing Through Exclusive Partnership with Sherman Abrams Laboratory in New Jersey and Surrounding Areas

Genetix Announces Transformation Into a Profitable, High-Growth Commercial Leader in Rare Disease Genetic Medicine

Genetix Biotherapeutics Reports Strong 2026 Commercial Growth, Achieves Profitability and Targets Multibillion-Dollar Expansion Genetix Biotherapeutics Inc., a commercial leader in genetic medicines for rare diseases with a primary focus on…

Read MoreGenetix Announces Transformation Into a Profitable, High-Growth Commercial Leader in Rare Disease Genetic Medicine

Northwell’s Feinstein Institutes’ Dr. Kevin J. Tracey Honored with Cold Spring Harbor Laboratory Double Helix Medal

Kevin J. Tracey Receives Prestigious Double Helix Medal for Pioneering Contributions to Bioelectronic Medicine Kevin J. Tracey, MD, widely recognized as the founding father of bioelectronic medicine and president and…

Read MoreNorthwell’s Feinstein Institutes’ Dr. Kevin J. Tracey Honored with Cold Spring Harbor Laboratory Double Helix Medal

C2N Diagnostics Launches FDA-Cleared PrecivityAD2® Test to Improve Alzheimer’s Disease Diagnosis in Symptomatic Patients

C2N Diagnostics Launches FDA-Cleared PrecivityAD2 Blood Test to Improve Alzheimer’s Disease Diagnosis C2N Diagnostics, LLC, a specialty diagnostics company focused on advancing innovative solutions for neurological conditions, has announced the…

Read MoreC2N Diagnostics Launches FDA-Cleared PrecivityAD2® Test to Improve Alzheimer’s Disease Diagnosis in Symptomatic Patients

Vyome Reports Significant Reduction in Q3 2026 Loss Per Share and Advances Lead VT-1953 Program

Vyome Holdings Reports Third-Quarter 2026 Financial Results, Advances VT-1953 Development and Strengthens Ophthalmology Pipeline Vyome Holdings, a clinical-stage biopharmaceutical company focused on developing treatments for immuno-inflammatory and rare diseases, has…

Read MoreVyome Reports Significant Reduction in Q3 2026 Loss Per Share and Advances Lead VT-1953 Program

Ollin Biosciences to Be Acquired, Advancing Development of Next-Generation Treatments for Vision-Threatening Eye Diseases

Ollin Biosciences to Be Acquired, Supporting the Development of Innovative Treatments for Vision-Threatening Eye Diseases Johnson & Johnson has entered into a definitive agreement to acquire Ollin Biosciences, Inc., a…

Read MoreOllin Biosciences to Be Acquired, Advancing Development of Next-Generation Treatments for Vision-Threatening Eye Diseases

Biocon Secures U.S. FDA Approval for Pebrilzo™ (Pertuzumab-qcay), Expanding Its Oncology Biosimilar Portfolio

Biocon Secures U.S. FDA Approval for Pebrilzo™ (Pertuzumab-qcay), Its Fifth Oncology Biosimilar, Expanding Access to HER2-Positive Breast Cancer Treatment Biocon Limited, an innovation-led global biopharmaceutical company, has announced that the…

Read MoreBiocon Secures U.S. FDA Approval for Pebrilzo™ (Pertuzumab-qcay), Expanding Its Oncology Biosimilar Portfolio